https://clinicaltrials.gov/ct2/show/NCT04368728?term=vaccine&cond=covid-19&draw=3
In an effort to address the global health crisis, we are developing a COVID-19 vaccine candidate based on our proprietary mRNA technology. Find out more about our development process, mRNA-based vacci
Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the pl
以上內容由「Cofacts 真的假的」訊息回報機器人與查證協作社群提供,以 CC授權 姓名標示-相同方式分享 4.0 (CC BY-SA 4.0) 釋出,於後續重製或散布時,原社群顯名及每一則查證的出處連結皆必須被完整引用。